SkinBioTherapeutics plc (LON:SBTX – Get Free Report) shares reached a new 52-week low on Wednesday. The stock traded as low as GBX 5 and last traded at GBX 5.35, with a volume of 1044465 shares changing hands. The stock had previously closed at GBX 5.50.
SkinBioTherapeutics Stock Down 2.6%
The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The firm has a market cap of £13.48 million, a P/E ratio of -32.50 and a beta of 0.10. The company’s 50-day simple moving average is GBX 8.74 and its 200 day simple moving average is GBX 9.54.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Recommended Stories
- Five stocks we like better than SkinBioTherapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
